VRTX — VERTEX PHARMACEUTICALS INC

Ownership history in HARDING LOEVNER LP  ·  45 quarters on record

This page tracks every 13F SEC filing in which HARDING LOEVNER LP reported a position in VERTEX PHARMACEUTICALS INC (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
3.28% (2023 Q1)
Avg. % of fund
1.98%
First filed
1999 Q1
Last filed
2025 Q4
Quarters held
45
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 391,865 -64,123 -14.1% 1.56% $177.7M $453.36
2025 Q3 REDUCED 455,988 -255,623 -35.9% 1.31% $178.6M $391.64
2025 Q2 ADDED 711,611 +13,152 +1.9% 2.13% $316.8M $445.20
2025 Q1 REDUCED 698,459 -125,168 -15.2% 2.59% $338.6M $484.82
41 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    VRTX price (monthly, adj. close)

Other funds also holding VRTX

As of 2025 Q4 — sorted by position size

Provident Investment Management, Inc. 3Y 7Y 6.16% Bellevue Group AG 3Y 7Y 5.85% Andrew Hill Investment Advisors, Inc. 3Y 4.28% Iron Triangle Partners LP 3Y 3.99% Atle Fund Management AB 3Y 7Y 3.32% MCRAE CAPITAL MANAGEMENT INC 3Y 7Y 3.29% Sofinnova Investments, Inc. 3Y 7Y 3.22% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 2.91% Birch Hill Investment Advisors LLC 3Y 7Y 2.89% NIA IMPACT ADVISORS, LLC 3Y 2.68%
← Back to HARDING LOEVNER LP Holdings